Barclays PLC Graphite Bio, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 15, 2024
BUY
$2.24 - $2.66 $108,447 - $128,781
48,414 Added 142.24%
82,451 $216,000
Q3 2023

Nov 07, 2023
BUY
$2.18 - $2.77 $61,916 - $78,673
28,402 Added 504.03%
34,037 $85,000
Q2 2023

Aug 03, 2023
SELL
$2.47 - $3.38 $43,657 - $59,741
-17,675 Reduced 75.83%
5,635 $15,000
Q1 2023

May 04, 2023
BUY
$1.85 - $3.21 $43,123 - $74,825
23,310 New
23,310 $57,000
Q2 2022

Aug 12, 2022
SELL
$2.14 - $5.23 $18,787 - $45,914
-8,779 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$5.1 - $13.06 $44,772 - $114,653
8,779 New
8,779 $44,000

Others Institutions Holding GRPH

# of Institutions
3
Shares Held
637K
Call Options Held
0
Put Options Held
0
View Full List

About Graphite Bio, Inc.

GRPH Quotes by TradingView
  • Ticker GRPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,211,200
  • Description
  • Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...
More about GRPH
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email